Figure 1.

Overall survival of 50 t-MN patients treated with azacitidine. Median survival was 25.6 months (range 1.1-61.1+) from initial diagnosis and 21 months (range 1–53.6+) from AZA start

Fianchi et al. Journal of Hematology & Oncology 2012 5:44   doi:10.1186/1756-8722-5-44
Download authors' original image